The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...

Psychedelics have been growing in popularity across North America for recreational and therapeutic use, with celebrities like ...

A new study links hallucinogen-related emergency department visits to a 21-fold increased risk of schizophrenia compared to ...

The most common side effects of INVEGA HAFYERA® include: injection site reactions, weight gain, headache, upper respiratory ...

ED visits related to hallucinogen use are linked to a 21-fold increased risk of schizophrenia spectrum disorder, results of a ...

Pharmaceutical company AbbVie announced that an experimental schizophrenia drug that was key to its $8.7 billion acquisition ...

Negative data cost AbbVie billions of dollars in market value and convinced analysts Bristol Myers had placed a better bet in ...

AbbVie Inc. shares fell the most in three years after two mid-stage trials of its drug to treat schizophrenia failed to meet ...

BMY has been having a good run for the past three months. The stock recently touched a 52-week high. We believe there is more ...

Shares in AbbVie slumped Monday after the company disclosed its psychiatric medicine emraclidine didn’t best placebo in two ...

The shocking failure of AbbVie’s emraclidine has investors questioning the Big Pharma’s long-term neuroscience strategy, ...

If it does prove to be the end of emraclidine for schizophrenia, that looks set to benefit Bristol-Myers Squibb, which ended ...